A5012567578- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- Infectious Diseases and Mycology
- Immunotherapy and Immune Responses
- Health Systems, Economic Evaluations, Quality of Life
- Prostate Cancer Treatment and Research
- Pleural and Pulmonary Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Phagocytosis and Immune Regulation
- Dermatological and COVID-19 studies
- Pharmaceutical Economics and Policy
- Inflammatory mediators and NSAID effects
- Quality and Safety in Healthcare
- Plant Pathogens and Fungal Diseases
- Parasitic Diseases Research and Treatment
- Mycobacterium research and diagnosis
Erasmus MC
2018-2025
Ghent University Hospital
2024-2025
Erasmus University Rotterdam
2018-2022
Abstract Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy successful 16. Mutations associated sotrovimab resistance were documented 6; viral replication continued after 30 days 5. Combination antibody may be required to avoid acquired patients.
Abstract Background Invasive aspergillosis (IA) by a triazole-resistant Aspergillus fumigatus is associated with high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy. Methods In prospective study, we evaluated the clinical value AsperGenius polymerase chain reaction (PCR) assay hematology patients from 12 centers. This PCR detects most frequent cyp51A mutations A. conferring azole resistance. Patients were included when computed tomography...
Galactomannan (GM) testing of bronchoalveolar lavage (BAL) fluid samples has become an essential tool to diagnose invasive pulmonary aspergillosis (IPA) and is part diagnostic guidelines. Enzyme-linked immunosorbent assays (ELISAs) (enzyme immunoassays [EIAs]) are commonly used, but they have a long turnaround time. In this study, we evaluated the performance automated chemiluminescence immunoassay (CLIA) with BAL samples. This was multicenter retrospective study in Netherlands Belgium. were...
Abstract Background Immunocompromised patients (ICPs) have an increased risk for a severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were extensively used in these patients, but data from randomized trials that focus on ICPs are lacking. We evaluated the clinical virological outcome of COVID-19 treated with mAbs across variants. Methods In this multicenter prospective cohort study, we enrolled B-cell– and/or T-cell–deficient casirivimab/imdevimab, sotrovimab, or...
An early diagnosis and treatment of invasive fungal disease (IFD) is associated with improved outcome, but the moderate sensitivity noninvasive diagnostic tests makes this challenging. Invasive procedures such as bronchoalveolar lavage (BAL) have a higher yield are not without risk. The detection sequencing microbial cell-free DNA (mcfDNA) may facilitate diagnosis. In prospective observational study, we collected plasma in 120 hours preceding or following BAL patients hematological...
Abstract Background The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. Methods Patients were randomly assigned receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Results Severe was observed 10 (20%) patients treated with compared 7 8 (88%) the IVIG...
Abstract Objectives Immunocompromised patients have an increased risk of severe or prolonged COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 7 days after symptom onset. Data on effectivity in immunocompromised with chronic non-resolving urgently needed. Here, we report outcome treated nirmatrelvir/ritonavir together high-titer convalescent plasma (CP) six Methods persisting (positive PCR Ct values <30 for ≥20 days) received off-label therapy...
An accurate diagnosis of invasive aspergillosis (IA) in patients with underlying hematological malignancies relies heavily on galactomannan detection. In this study, we compared the VirCLIA chemiluminescence immunoassay (CLIA) frequently used Platelia enzyme-linked immunosorbent assay (ELISA) serum from hematology suspected IA. Patients were categorized according to EORTC/MSGERC 2020 definitions into proven/probable IA and possible/no The first cohort included 161 at four centers,...
During the COVID-19 pandemic, trials on convalescent plasma (ConvP) were performed without preceding dose-finding studies. This study aimed to assess potential protective dosing regimens by constructing a population pharmacokinetic (popPK) model describing anti-SARS-CoV-2 antibody titers following administration of ConvP or hyperimmune globulins (COVIg).
Abstract Background Sotrovimab is a monoclonal antibody that neutralizes SARS-CoV-2 by binding to highly conserved epitope in the receptor domain. It retains activity against Omicron BA.1 variant and used treat immunocompromised patients as they are at increased risk for severe outcome of COVID-19. Methods We studied viral evolution 47 infected with or 2 treated sotrovimab. PCR was performed baseline weekly thereafter until Ct-value ≥ 30. All RNA samples were sequenced determine occurrence...
Abstract Background Invasive pulmonary aspergillosis (IPA) is a relatively common infection in patients with acute myeloid leukaemia (AML), and associated high mortality rates. Optimising early detection key to reduce the burden of IPA this population. In retrospective cohort study, we evaluated added value baseline chest CT before start classical induction chemotherapy. Methods Adult receiving first‐line intensive chemotherapy for AML were included if scan was available (±7 days). Data...
The IA-DUET study aimed to compare azole-echinocandin combination with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring therapy when resistance unknown. low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints enhance efficiency.
Abstract Background During the COVID-19 pandemic, trials on convalescent plasma (ConvP) were performed without preceding dose-finding studies. This study aimed to assess potential protective dosing regimens by constructing a population pharmacokinetic (popPK) model describing neutralizing antibody (Nab) titers following administration of ConvP or hyperimmune globulins(COVIg). Methods Immunocompromised patients, testing negative for anti-SARS-CoV-2 spike antibodies despite vaccination...
Summary Background Severely immunocompromised patients are at risk for severe COVID-19. Benefit from convalescent plasma in these is suggested but data randomised trials lacking. The aim of this study to determine efficacy SARS-CoV-2 hyperimmune globulin (“COVIG”) treatment severely immunocompromised, hospitalised COVID-19 patients. Methods In randomised, controlled, double-blind, multicentre, phase 3 trial, who were with symptomatic randomly assigned (1:1) receive 15 grams COVIG or...
Abstract Poster session 1, September 21, 2022, 12:30 PM - 1:30 Objectives Prompt detection of azole-resistant Aspergillus fumigatus will result in the timely start active treatment and may improve survival invasive aspergillosis (IA). The use a multiplex polymerase chain reaction (PCR) targeting species DNA as well two most prevalent azole resistance- associated mutations (RAMs) cyp51A gen (TR34/L98H TR46/Y121F/T289A) could shorten time to detect IA. Methods In prospective study 12 Dutch...